
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Expert Market Research report, titled “Lissamine Green Manufacturing Plant Project Report 2025 Edition: Industry Trends, Capital Investment, Price Trends, Manufacturing Process, Raw Materials Requirement, Plant Setup, Operating Cost, and Revenue Statistics” includes various aspects that are critical for establishing a Lissamine Green plant. These include infrastructure requirements, transportation requirements, utility specifications, and financial and economic analysis, among others.
The demand for Lissamine Green (LG) is rising due to the increasing prevalence of dry eye disease (DED), which affects approximately 1.4 billion people globally, with significant rates in older adults. In the United States, approximately 16 million people are affected, translating to about 8.1% of the population. In Canada, around 22% of the population experiences DED, which equates to roughly 7.5 million individuals. The United Kingdom reports a prevalence of about 18%, affecting nearly 12 million people. In India, the situation is more pronounced, with an estimated 32% of the population suffering from DED, which amounts to over 400 million individuals given its large population. In China, around 20.1% of the population experiences dry eye symptoms, translating to approximately 290 million people, influenced by increased screen time. Brazil sees a prevalence of about 12.8%, impacting around 27 million individuals. In Saudi Arabia, the prevalence is alarmingly high, ranging from 32.1% to 62.4%, affecting between 10 million and 20 million people. Finally, in Australia, about 9.04% of the population suffers from DED, which corresponds to roughly 2.3 million individuals. These statistics underscore the need for effective management strategies across different regions.
LG is a preferred diagnostic tool for evaluating ocular surface health, as it safely stains damaged epithelial cells with minimal irritation. Its effectiveness and excellent safety profile make it a "gold standard" in clinical assessments, often used alongside fluorescein staining. As awareness of DED grows and more patients seek relief, the demand for Lissamine Green is expected to continue increasing in both clinical and research settings.
Other elements to consider while establishing a Lissamine Green plant include raw material sourcing, workforce planning, and packaging. The production of Lissamine Green relies on several key raw materials, including 2-chlorobenzaldehyde, 4-aminobenzenesulfonic acid, and ethylamine. These components are typically sourced from chemical manufacturers dealing in organic compounds. For instance, 2-chlorobenzaldehyde is often derived from chlorobenzene through a chlorination process, while 4-aminobenzenesulfonic acid can be produced from sulfanilic acid. Ethylamine is commonly obtained through the reaction of ammonia with ethanol.
Moreover, to help stakeholders determine the economics of a Lissamine Green plant, project funding, capital investments, and operating expenses are analyzed. Projections for income and expenditure, along with a detailed breakdown of fixed and variable costs, direct and indirect expenses, and profit and loss analysis, enable stakeholders to comprehend the financial health and sustainability of a business. These projections serve as a strategic tool for evaluating future profitability, assessing cash flow needs, and identifying potential financial risks.
Lissamine Green (LG) is a synthetic organic dye widely used in ophthalmology, primarily for staining dead and degenerate cells on the ocular surface. It is particularly effective in diagnosing conditions such as dry eye disease and ocular surface disorders, as it selectively stains epithelial cells that are damaged or lack protective mucin. The dye is well-tolerated by patients compared to other staining agents like Rose Bengal, making it a preferred option for conjunctival and corneal assessments. In addition to its medical applications, Lissamine Green is also used in cosmetics and food products due to its safety profile and visibility. Lissamine Green was first noted for its protein-staining properties in 1957. Its application in ophthalmology began in 1967 when it was introduced for assessing endothelial cell viability. By 1973, it gained recognition for its effectiveness in staining corneal and conjunctival cells, solidifying its role in clinical diagnostics and patient care.
Lissamine Green (LG) is a synthetic organic dye known by its dark green powder form. Its chemical formula is C37H34ClN2O6S2 with a molecular weight of 702.3 g/mol. The dye has a solubility of approximately 0.1% in water at room temperature and is stable under normal conditions, with a pH range of 4 to 6.5 for optimal performance. Lissamine Green has a total dye content exceeding 80% and low water-insoluble matter, typically less than 0.2%. Its peak absorption occurs around 630 nm, which makes it effective for visualising stained tissues in ophthalmic diagnostics or particularly in identifying damaged epithelial cells.
The production of Lissamine Green starts with the procurement of raw materials, including specific chemical precursors such as aromatic amines and sulfonic acids. The synthesis process begins by combining these precursors in a reaction vessel, where catalysts and solvents are added to facilitate the chemical reaction. This reaction typically occurs under controlled temperature and pressure conditions to optimize yield. Following synthesis, the mixture undergoes purification, which involves filtering out impurities and employing techniques like distillation to isolate the dye effectively.
Once purified, the Lissamine Green is dried under controlled conditions to achieve a stable powder form, ensuring that moisture content is reduced. Quality control is then conducted to test for colour consistency, purity levels (ideally above 80%), and solubility (approximately 0.1% in water at room temperature). After passing quality checks, the final product is packaged in appropriate containers, ready for distribution to pharmaceutical industries.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Lissamine Green (LG) is increasingly used in ophthalmology for diagnosing and managing dry eye disease (DED), which affects approximately 10-20% of individuals over 40 years old, translating to around 30 million people in the United States alone as of 2024. Studies have shown that the prevalence of DED symptoms can reach as high as 60.4% in specific populations, such as postmenopausal women. LG is particularly effective in assessing conjunctival staining, a key indicator of ocular surface integrity, with studies indicating staining rates of up to 81.3% in patients with Sjogren's syndrome. Furthermore, a recent clinical trial demonstrated that Lissamine Green help in identifying significant ocular surface damage in up to 70% of patients presenting with severe dry eye symptoms. Government reports, including the TFOS DEWS II Report (2017), also advocate for LG as a standard practice in ocular assessments, highlighting its role in enhancing diagnostic accuracy and treatment compliance. By providing precise evaluations, Lissamine Green supports improved patient outcomes and quality of life for millions suffering from DED globally.
A detailed overview of production cost analysis that evaluates the manufacturing process of Lissamine Green is crucial for stakeholders considering entry into this sector. Furthermore, stakeholders can make informed decisions based on the latest economic data, technological innovations, production process, requirements of raw materials, utility and operating costs, capital investments by major players, pricing strategies, and profit margins. For instance, in January 2025, Stuart Therapeutics announced the completion of its Phase 3 clinical trial for its lead therapeutic candidate, ST-100 (vezocolmitide), aimed at treating dry eye disease. The trial involved 500 participants and assessed the efficacy and safety of vezocolmitide, a collagen mimetic peptide designed to repair disease-damaged collagen in the eye. This advancement highlights the potential of vezocolmitide as a fast-acting treatment option for millions suffering from dry eye disease. This could shift treatment paradigms in dry eye disease, potentially reducing reliance on Lissamine Green for diagnostic purposes. If ST-100 proves effective, it may decrease demand for Lissamine Green in clinical settings as new therapies take precedence.
Below are the sections that further detail the comprehensive scope of the prefeasibility report for a Lissamine Green production plant:
Market Dynamics and Trends: Factors such as the rapidly growing geriatric population and the increasing demand for ophthalmic care significantly affect market conditions in the Lissamine Green sector. The World Health Organization projects that by 2030, 1 in 6 individuals globally will be aged 60 or older, with the elderly population expected to double from 1 billion in 2020 to 2.1 billion by 2050. In India alone, the elderly population is projected to rise from around 153 million to 347 million, making up approximately 20% of the total population by mid-century. This demographic shift leads to a higher prevalence of eye disorders, including dry eye syndrome, particularly among older adults who experience decreased tear production and increased exposure to environmental stressors. The global dry eye syndrome market growth is driven by advancements in ophthalmic technology and a heightened focus on eye health. As more individuals seek effective diagnostic tools for managing ocular surface diseases, the demand for Lissamine Green is anticipated to rise significantly. Understanding these demands and trends helps businesses align their production plans in the Lissamine Green market.
Profiling of Key Industry Players: Leading manufacturers like Biotech Healthcare, Ophtechnics Unlimited, and Carl Roth are included in the Lissamine Green report. Recently, the market has seen a significant uptick in the use of Lissamine Green (LG) due to its effectiveness in diagnosing ocular surface diseases, particularly dry eye syndrome. Clinical studies have validated LG as a reliable dye for assessing conjunctival staining, demonstrating its superiority over traditional dyes like Rose Bengal.
The dye is particularly favoured for its safety and minimal ocular discomfort, making it suitable for repeated applications in clinical settings. Research indicates that LG can effectively illuminate damaged epithelial cells, providing crucial insights into conditions like dry eye disease, which affects millions globally. The ongoing development of a new grading scale for LG by research organisations aims to enhance its application in clinical trials, further solidifying its role as a primary endpoint in evaluating ocular surface integrity. This growing recognition underscores the importance of Lissamine Green in both clinical practice and research within ophthalmology.
Economic Analysis: Capital expenditure (CAPEX) analysis provides stakeholders the knowledge about required investments in advanced technologies, efficient machinery, and necessary infrastructure. Investing in high-capacity mixing equipment, such as a continuous mixer or high-shear mixer, can improve production efficiency by 20-30%. Investing in energy-efficient systems, such as combined heat and power (CHP) systems could reduce energy consumption by up to 30%, as these systems use waste heat from production processes to generate electricity and provide heating.
Fluctuations in Lissamine Green prices are influenced by several key factors, including raw material costs, manufacturing processes, and market demand. Variations in the prices of essential raw materials, such as 2-chlorobenzaldehyde and 4-aminobenzenesulfonic acid, can impact overall pricing due to supply chain disruptions. Additionally, advancements in manufacturing techniques may lead to cost efficiencies or increased costs. The rising prevalence of dry eye disease and an ageing population drive demand for Lissamine Green, potentially leading to price increases if supply does not keep pace. Regulatory changes and competition among manufacturers also contribute to price fluctuations. Understanding these elements is essential for stakeholders to navigate market trends effectively.
Establishing a Lissamine Green manufacturing facility requires a comprehensive financial investment that encompasses various elements critical to the project's success. The following sections detail these components:
Projected profit margins and effective product pricing strategies improve overall profitability. Manufacturers might target a profit margin of around 20-30%, achieved through strategic pricing based on raw material costs and prevailing market demand. Effective pricing strategies should consider fluctuations in raw material prices and competitive positioning within the market.
The establishment of a Lissamine Green manufacturing facility must comply with various regulatory frameworks that govern production standards. Key regulations include the REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) in the European Union, which mandates that manufacturers register chemical substances and demonstrate their safety. Additionally, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK classifies Lissamine Green as a medicinal product, requiring compliance with specific guidelines for manufacturing and marketing.
Moreover, facilities must adhere to Good Manufacturing Practices (GMP) to ensure product quality and safety. This includes proper handling, storage, and disposal of hazardous materials, as outlined in safety data sheets. Compliance with environmental regulations is also critical, particularly concerning waste management and emissions. These regulatory requirements are essential for establishing a compliant and efficient Lissamine Green production facility.
This prefeasibility report aims to equip potential investors and existing manufacturers with crucial insights to make informed decisions in the Lissamine Green industry.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Basic Plan
USD 2,699
USD 2,429
Get Startedtax inclusive*
Raw Material and Product Specification, Raw material consumption, Process flow diagram
Machinery Cost, Working Capital
Utilities consumption, Operating cost, Overheads, Financing Charges, GSA , Packaging
Premium Plan
USD 3,699
USD 3,329
Get Startedtax inclusive*
Key Processing Information, Capital Investment Analysis, Conversion Cost Analysis
Raw material consumption and prices, Utilities consumption breakdown, By-Product Credit, Labour Charges Breakdown
Land and Site Cost, Equipment Cost, Auxiliary Equipment Cost, Contingency, Engineering and Consulting Charges
Enterprise Plan
USD 4,799
USD 4,079
Get Startedtax inclusive*
Key Processing Information, Capital Investment Analysis, Conversion Cost Analysis, Variable Cost Breakdown, Investing Cost Breakdown,
Breakdown of machinery cost by equipment, Auxiliary Equipment Cost, Piping, Electrical, Instrumentation
Cost of Construction, Plant Building, Site Development Charges
Land Cost, Development Charges
Dynamic Spreadsheet (Unlocked)
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Basic Plan
USD 2,699
USD 2,429
Key Processing Information
Raw Material and Product Specification, Raw Material Consumption, Process Flow Diagram
Capital Investment Analysis
Machinery Cost, Working Capital
Conversion Cost Analysis
Utilities Consumption, Operating Cost, Overheads, Financing Charges, GSA , Packaging
Premium Plan
USD 3,699
USD 3,329
All Contents of Basic Report
Key Processing Information, Capital Investment Analysis, Conversion Cost Analysis
Variable Cost Breakdown
Raw Material Consumption and Prices, Utilities Consumption, Breakdown By-Product Credit, Labour Charges Breakdown
Investing Cost Breakdown
Land and Site Cost, Equipment Cost, Auxiliary Equipment Cost, Contingency, Engineering and Consulting Charges
Enterprise Plan
USD 4,799
USD 4,079
Includes all Report Content
Key Processing Information, Capital Investment Analysis, Conversion Cost Analysis, Variable Cost Breakdown, Investing Cost Breakdown,
Equipment Cost Breakdown
Breakdown of Machinery Cost By Equipment, Auxiliary Equipment Cost, Piping, Electrical, Instrumentation
Land and Construction Cost Details
Land Cost, Development Charges, Cost of Construction, Plant Building, Site Development Charges
Dynamic Excel Cost Model
Dynamic Spreadsheet (Unlocked)
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share